BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sevim E, Willis R, Erkan D. Is there a role for immunosuppression in antiphospholipid syndrome? Hematology Am Soc Hematol Educ Program 2019;2019:426-32. [PMID: 31808842 DOI: 10.1182/hematology.2019000073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Erton ZB, Erkan D. Treatment advances in antiphospholipid syndrome: 2022 update. Current Opinion in Pharmacology 2022;65:102212. [DOI: 10.1016/j.coph.2022.102212] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Barreno-rocha SG, Guzmán-silahua S, Rodríguez-dávila S, Gavilanez-chávez GE, Cardona-muñoz EG, Riebeling-navarro C, Rubio-jurado B, Nava-zavala AH. Antiphospholipid Antibodies and Lipids in Hematological Malignancies. IJMS 2022;23:4151. [DOI: 10.3390/ijms23084151] [Reference Citation Analysis]
3 Cervera R, Rodríguez-pintó I, Legault K, Erkan D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Lupus 2020;29:1594-600. [DOI: 10.1177/0961203320951260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xourgia E, Tektonidou MG. Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep 2020;22:51. [PMID: 32699944 DOI: 10.1007/s11926-020-00935-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Demir S, Keskin A, Sağ E, Kaya Akca Ü, Atalay E, Cüceoğlu MK, Batu Akal ED, Özen S, Bilginer Y. The challenges in diagnosing pediatric primary antiphospholipid syndrome. Lupus 2022;:9612033221108853. [PMID: 35746827 DOI: 10.1177/09612033221108853] [Reference Citation Analysis]
6 Stanescu C, Andronesi AG, Jurcut C, Gherghiceanu M, Vornicu A, Burcea FA, Andronesi TD, Lupusoru GE, Iliuta L, Sorohan BM, Obrisca B, Ismail G. Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature. Medicina (Kaunas) 2021;57:912. [PMID: 34577835 DOI: 10.3390/medicina57090912] [Reference Citation Analysis]
7 Zhang B, Lang Y, Zhang W, Cui L, Deng F. Characteristics and Management of Autoimmune Disease-Associated Cerebral Venous Sinus Thrombosis. Front Immunol 2021;12:671101. [PMID: 34367137 DOI: 10.3389/fimmu.2021.671101] [Reference Citation Analysis]
8 Madison JA, Duarte-García A, Zuo Y, Knight JS. Treatment of thrombotic antiphospholipid syndrome in adults and children. Curr Opin Rheumatol 2020;32:215-27. [PMID: 32187042 DOI: 10.1097/BOR.0000000000000702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ghansah H, Debreceni IB, Fejes Z, Nagy B Jr, Kappelmayer J. The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets. Int J Mol Sci 2021;22:8955. [PMID: 34445660 DOI: 10.3390/ijms22168955] [Reference Citation Analysis]